Search research articles
Contact Us
Filters
Showing results (141-150 of 217) with videos related to
Page
of 22
Sort By:
ACR Open Rheumatology
|
February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
Christopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology
|
February 12, 2010
Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008
Christopher T Ritchlin, Abrar A Qureshi, Kurt de Vlam, et al.
Rheumatology (Oxford, England)
|
April 5, 2018
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
Douglas J Veale, Dennis McGonagle, Iain B McInnes, et al.
Clinical Rheumatology
|
June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 12, 2011
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Ya-Hui Chiu, Kofi A Mensah, Edward M Schwarz, et al.
Plos One
|
October 22, 2014
Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy
Alexander Rosenberg, Hongtao Fan, Yahui G Chiu, et al.
The Journal of Rheumatology
|
September 17, 2010
Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry
Soumya M Reddy, Allen P Anandarajah, Mark C Fisher, et al.
Annals of the Rheumatic Diseases
|
August 25, 2016
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, et al.
Arthritis and Rheumatism
|
December 1, 2007
Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography
Steven T Proulx, Edmund Kwok, Zhigang You, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
Laura C Coates, Iain B McInnes, Joseph F Merola, et al.
Page
of 22
Search research articles
Search
Showing results (141-150 of 217) with videos related to
Sort By:
Page
of 22
ACR Open Rheumatology
|
February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
Christopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology
|
February 12, 2010
Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008
Christopher T Ritchlin, Abrar A Qureshi, Kurt de Vlam, et al.
Rheumatology (Oxford, England)
|
April 5, 2018
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
Douglas J Veale, Dennis McGonagle, Iain B McInnes, et al.
Clinical Rheumatology
|
June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 12, 2011
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Ya-Hui Chiu, Kofi A Mensah, Edward M Schwarz, et al.
Plos One
|
October 22, 2014
Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy
Alexander Rosenberg, Hongtao Fan, Yahui G Chiu, et al.
The Journal of Rheumatology
|
September 17, 2010
Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry
Soumya M Reddy, Allen P Anandarajah, Mark C Fisher, et al.
Annals of the Rheumatic Diseases
|
August 25, 2016
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, et al.
Arthritis and Rheumatism
|
December 1, 2007
Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography
Steven T Proulx, Edmund Kwok, Zhigang You, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
Laura C Coates, Iain B McInnes, Joseph F Merola, et al.
Page
of 22